Floatz logo

5-FLUOROCYTOSINE

Anaplastic Astrocytoma

NRG OncologySmall moleculePhase 2/3Dormant
CCC
52/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

37 Active assets in the Anaplastic Astrocytoma cohort.

Asset / SponsorPhaseRating
Irinotecan
City of Hope Medical Center
Phase 2/3BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
(+)-VINCRISTINE
Novartis Pharmaceuticals
Phase 2/3BB
Carboplatin
Oliver Jonas
Phase 2BB
gsk1120212
National Cancer Institute (NCI)
Phase 4BB

View all 50 →

Same molecule, other indications

5-FLUOROCYTOSINE is also rated in:

glioblastomaDormant
CCC
Indicative ·
54 / 100
View asset →
anaplastic oligoastrocytomaDormant
CCC
Indicative ·
51 / 100
View asset →
anaplastic oligodendrogliomaDormant
CCC
Indicative ·
51 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →